View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 11, 2016

Karuna begins proof-of-concept study of KarXT for Alzheimer’s disease

US-based clinical-stage drug development company Karuna Pharmaceuticals has begun its proof-of-concept study of KarXT for Alzheimer’s disease by dosing its first patient.

US-based clinical-stage drug development company Karuna Pharmaceuticals has begun its proof-of-concept study of KarXT for Alzheimer’s disease by dosing its first patient.

KarXT features a combination of xanomeline, which acts as a muscarinic acetylcholine receptor agonist, and trospium chloride, a muscarinic receptor antagonist that has been shown not to enter the central nervous system (CNS).

The muscarinic receptors in the nervous system fuse with the acetylcholine (a neurotransmitter) and an activation of muscarinic receptors outside of the brain leads to side effects such as GI adverse events.

The randomised, double-blind, multiple-dose trial will study the tolerability of KarXT compared to xanomeline alone in 70 healthy individuals.

"By combining xanomeline with trospium chloride, we aim to unlock the therapeutic potential of M1/M4 agonists and address the significant unmet need in treating these disorders."

The volunteers will undergo an in-clinic treatment for nine days. After a two-day run-in period with trospium alone, the volunteers will be administered with xanomeline and either trospium chloride or placebo.

Karuna CEO Andrew Miller said: “In clinical studies, xanomeline has shown robust efficacy in people with schizophrenia and in people with Alzheimer’s disease, demonstrating the immense potential of targeting the M1/M4 muscarinic acetylcholine receptors; however, the muscarinic field has been stymied by tolerability concerns caused by activation of muscarinic receptors in peripheral tissues.

“By combining xanomeline with trospium chloride, we aim to unlock the therapeutic potential of M1/M4 agonists and address the significant unmet need in treating these disorders.”

The company is expecting to report the top-line results of the proof-of-concept study by the end of this year.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena